News coverage about MediciNova (NASDAQ:MNOV) has trended somewhat positive on Friday, according to Accern. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MediciNova earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.7021295767526 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of MediciNova opened at $10.39 on Friday, MarketBeat reports. MediciNova has a 52 week low of $10.35 and a 52 week high of $10.59.
Several research firms have recently weighed in on MNOV. B. Riley began coverage on shares of MediciNova in a research note on Wednesday, March 28th. They set a “buy” rating and a $22.00 price target for the company. BidaskClub downgraded shares of MediciNova from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, March 21st. Finally, ValuEngine raised shares of MediciNova from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd.
MediciNova Company Profile
MediciNova, Inc, a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company's product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders consisting of primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction.
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.